JP2012513467A5 - - Google Patents

Download PDF

Info

Publication number
JP2012513467A5
JP2012513467A5 JP2011543601A JP2011543601A JP2012513467A5 JP 2012513467 A5 JP2012513467 A5 JP 2012513467A5 JP 2011543601 A JP2011543601 A JP 2011543601A JP 2011543601 A JP2011543601 A JP 2011543601A JP 2012513467 A5 JP2012513467 A5 JP 2012513467A5
Authority
JP
Japan
Prior art keywords
resistant
bacterium
pharmaceutical composition
clostridium difficile
antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011543601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513467A (ja
JP5670914B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/068747 external-priority patent/WO2010075215A1/en
Publication of JP2012513467A publication Critical patent/JP2012513467A/ja
Publication of JP2012513467A5 publication Critical patent/JP2012513467A5/ja
Application granted granted Critical
Publication of JP5670914B2 publication Critical patent/JP5670914B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011543601A 2008-12-22 2009-12-18 グラム陽性菌感染症を処置するための新規抗菌剤 Expired - Fee Related JP5670914B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13987508P 2008-12-22 2008-12-22
US61/139,875 2008-12-22
PCT/US2009/068747 WO2010075215A1 (en) 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections

Publications (3)

Publication Number Publication Date
JP2012513467A JP2012513467A (ja) 2012-06-14
JP2012513467A5 true JP2012513467A5 (enExample) 2013-10-03
JP5670914B2 JP5670914B2 (ja) 2015-02-18

Family

ID=41718893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011543601A Expired - Fee Related JP5670914B2 (ja) 2008-12-22 2009-12-18 グラム陽性菌感染症を処置するための新規抗菌剤

Country Status (26)

Country Link
US (3) US8507647B2 (enExample)
EP (2) EP2674437A1 (enExample)
JP (1) JP5670914B2 (enExample)
KR (1) KR101717795B1 (enExample)
CN (1) CN102325787B (enExample)
AR (1) AR074833A1 (enExample)
AU (1) AU2009330245C1 (enExample)
BR (1) BRPI0923567A2 (enExample)
CA (1) CA2747965C (enExample)
CY (1) CY1114883T1 (enExample)
DK (1) DK2379580T3 (enExample)
ES (1) ES2442167T3 (enExample)
HR (1) HRP20131170T1 (enExample)
IL (1) IL213638A0 (enExample)
MX (1) MX2011006803A (enExample)
NZ (1) NZ594019A (enExample)
PL (1) PL2379580T3 (enExample)
PT (1) PT2379580E (enExample)
RS (1) RS53152B (enExample)
RU (1) RU2512396C2 (enExample)
SG (1) SG172299A1 (enExample)
SI (1) SI2379580T1 (enExample)
SM (1) SMT201400037B (enExample)
TW (1) TWI444198B (enExample)
WO (1) WO2010075215A1 (enExample)
ZA (1) ZA201104693B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013157188A (ru) 2011-05-26 2015-07-10 Кьюбист Фармасьютикалз, Инк. Композиции св-183,315 и относящиеся к ним способы
US10377699B2 (en) * 2013-11-06 2019-08-13 The University Of Hong Kong Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue
WO2015172047A1 (en) * 2014-05-08 2015-11-12 Merck Sharp & Dohme Corp. Cyclic peptide compounds and related methods, salts and compositions
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
MX386103B (es) * 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
US10098890B2 (en) 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
IT201600127655A1 (it) * 2016-12-16 2018-06-16 Gnosis Spa Processo per la purificazione di antibiotici lipopolipeptidici
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
RU2762182C1 (ru) * 2020-12-08 2021-12-16 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4812470A (en) 1982-02-27 1989-03-14 Beecham Group P.L.C. Antibacterial monic acid derivatives
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4396543A (en) * 1982-05-21 1983-08-02 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
IL68700A0 (en) * 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CS276978B6 (en) 1984-10-09 1992-11-18 Lilly Co Eli Process for preparing a-21978c antibiotic derivative
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
CA2043762C (en) 1990-06-07 2001-05-29 Adam J. Kreuzman Lipopeptide deacylase
AU7497594A (en) 1993-08-13 1995-03-14 Smithkline Beecham Plc Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2248348C (en) 1996-03-08 2008-06-10 Fujisawa Pharmaceutical Co., Ltd. Process for the deacylation of cyclic lipopeptides
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
HK1040363B (en) 1998-09-25 2007-01-26 Cubist Pharmaceuticals Llc Use of daptomycin
JP2003520353A (ja) 1999-11-03 2003-07-02 ザ ウィタカー コーポレーション マルチファイバアレー用光電子モジュール
WO2001044271A2 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Daptomycin analogs and their use as antibacterial agents
KR20020063228A (ko) 1999-12-15 2002-08-01 큐비스트 파마슈티컬즈 인코포레이티드 항균제로서 리포펩티드
US6911525B2 (en) * 1999-12-15 2005-06-28 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1423137B1 (en) 2001-08-06 2009-04-29 Cubist Pharmaceuticals, Inc. Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
EP1814588A2 (en) * 2004-11-12 2007-08-08 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides

Similar Documents

Publication Publication Date Title
JP2012513467A5 (enExample)
RU2011130278A (ru) Новые противобактериальные средства для лечения грамположительных инфекций
CN102871996A (zh) 一种抗菌药物组合物及其应用
CN108823124B (zh) 一株对革兰阳性耐药菌具有广谱抗菌活性的表皮葡萄球菌及其筛选方法和应用
Marsilio et al. Coagulase-positive and coagulase-negative Staphylococci animal diseases
JP2017519730A5 (enExample)
EP2822582B1 (en) Multivalent vaccine protection from staphylococcus aureus infection
Kazemi et al. Antibacterial effect of silver nanoparticles along with protein synthesis-inhibiting antibiotics on Staphylococcus aureus isolated from cattle mastitis
RU2004118716A (ru) Лечение инфекции, вызываемой микроорганизмами
MXPA06000691A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas.
KR101258692B1 (ko) 항생제 저항성 포도상구균(mrsa)억제 유산균 바이셀라 비리데센스
JP2024009968A5 (enExample)
Delpech et al. Bactericidal activity and synergy studies of peptide AP-CECT7121 against multi-resistant bacteria isolated from human and animal soft tissue infections
JP2017533177A5 (enExample)
WO2013041663A3 (de) Modifizierte apidaecinderivate als antibiotische peptide
Ebani Biology and pathogenesis of Staphylococcus infection
MX2007009059A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos.
Bell et al. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008)
Leite et al. N-acetylcysteine and vancomycin alone and in combination against staphylococci biofilm
Sibanda et al. In vitro antibacterial activities of crude extracts of Garcinia kola seeds against wound sepsis associated Staphylococcus strains
Jung et al. Antibacterial activity of LCB01-0062, a novel oxazolidinone
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
CN109620827B (zh) 杂环丙烯酮类化合物作为抗菌剂的用途
Hussain et al. Resistance pattern of 3rd generation cephalosporins
Bhattacharyya et al. Antibiotics business: A glimpse